Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 8/20 | 0.48 |
| ▸ | PPARD | Q03181 | 5/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011282 | 1.00 | CNR1 (0.64) | CNR1SMN1; SMN2NOTUMMAPK1USP2 | |
| SCHEMBL14859926 | 1.00 | CNR1 (0.64) | CNR1SMN1; SMN2NOTUMMAPK1USP2 | |
| SCHEMBL15212339 | 0.90 | NOTUM (0.58) | CNR1SMN1; SMN2NOTUMUSP30CASR | |
| SCHEMBL17846589 | 0.88 | CNR1 (0.62) | CNR1SMN1; SMN2NOTUMMAPK1USP2 | |
| SCHEMBL16422448 | 0.87 | NOTUM (0.55) | CNR1SMN1; SMN2NOTUMMAPK1PPARA | |
| SCHEMBL6365484 | 0.87 | CNR1 (0.51) | CNR1SMN1; SMN2MAPK1USP2PPARA | |
| SCHEMBL16570341 | 0.87 | CNR1 (0.51) | CNR1SMN1; SMN2USP2PPARAPPARD | |
| SCHEMBL21526469 | 0.87 | CNR1 (0.51) | CNR1SMN1; SMN2USP2PPARAPPARD | |
| SCHEMBL21526427 | 0.87 | CNR1 (0.51) | CNR1SMN1; SMN2USP2PPARAPPARD | |
| SCHEMBL16422346 | 0.87 | NOTUM (0.55) | CNR1SMN1; SMN2NOTUMMAPK1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-105960404-B | The inhibitor of bruton's tyrosine kinase | 药品循环有限责任公司 | 2019-09-03 | — | — | CN | disclosed |
| EP-3464274-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| CN-108699032-A | Polycyclic T L R7/8 antagonists and their use in treating immune disorders | 默克专利有限公司 | 2018-10-23 | — | — | CN | disclosed |
| WO-2017202703-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| CN-104334546-A | Novel ring-substituted N-pyridyl amides as kinase inhibitors | NOVARTIS AG | 2015-02-04 | — | — | CN | disclosed |
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | CNR1 4836/4885SMN1; SMN2 1828/4885NOTUM 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.